Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. The Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Its focus on food safety Roka delivers accurate and reliable test results for food pathogens regardless of sample type.


Company Growth (employees)
Type
Public
HQ
Warren, US
Founded
2009
Size (employees)
90 (est)
Roka Bioscience was founded in 2009 and is headquartered in Warren, US

Key People at Roka Bioscience

Paul G. Thomas

Paul G. Thomas

Chairman of the Board
David R. Patterson

David R. Patterson

Vice President of Manufacturing Operations
Lars Boesgaard

Lars Boesgaard

Vice President, CFO

Roka Bioscience Office Locations

Roka Bioscience has an office in Warren
Warren, US (HQ)
20 Independence Boulevard

Roka Bioscience Data and Metrics

Roka Bioscience Financial Metrics

Roka Bioscience's revenue was reported to be $7.2 m in FY, 2016 which is a 21% increase from the previous period.
USD

Revenue (FY, 2016)

7.2 m

Revenue growth (FY, 2015 - FY, 2016), %

21%

Gross profit (FY, 2016)

(732 k)

Gross profit margin (FY, 2016), %

(10%)

Net income (FY, 2016)

(30.8 m)

EBIT (FY, 2016)

(29.5 m)

Market capitalization (26-Jun-2017)

13.1 m

Closing share price (26-Jun-2017)

2.5

Cash (31-Dec-2016)

8.8 m
Roka Bioscience's current market capitalization is $13.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

5.1 m6 m7.2 m

Revenue growth, %

18%21%

Cost of goods sold

8 m

Gross profit

(732 k)

Gross profit Margin, %

(10%)

R&D expense

7.3 m

General and administrative expense

17.7 m

Operating expense total

36.6 m41.3 m36.7 m

EBIT

(31.6 m)(35.3 m)(29.5 m)

EBIT margin, %

(625%)(590%)(407%)

Interest expense

(1.6 m)

Interest income

(1.6 m)

Pre tax profit

(31 m)

Income tax expense

(245 k)

Net Income

(32.2 m)(36.6 m)(30.8 m)
USDFY, 2014FY, 2015FY, 2016

Cash

7.5 m3.4 m8.8 m

Inventories

4.9 m3.9 m3.7 m

Current Assets

51.4 m42.1 m35.1 m

PP&E

12.2 m9.8 m7.8 m

Goodwill

360 k

Total Assets

103.8 m74.6 m61.8 m

Accounts Payable

1.1 m675 k1.3 m

Current Liabilities

13.9 m18.6 m15.1 m

Additional Paid-in Capital

212.1 m214.6 m245.1 m

Retained Earnings

(133 m)(169.6 m)(208.1 m)

Total Equity

36.9 m

Financial Leverage

1.7 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(32.2 m)(36.6 m)(30.8 m)

Depreciation and Amortization

4.2 m6.2 m5.8 m

Accounts Receivable

(220 k)(122 k)(207 k)

Inventories

(2.8 m)690 k(638 k)

Accounts Payable

(465 k)4.1 m(362 k)

Cash From Operating Activities

(25.2 m)(4.1 m)(22.8 m)

Purchases of PP&E

(171 k)(277 k)

Cash From Investing Activities

(60.5 m)20.1 m12.4 m

Cash From Financing Activities

58.7 m(393 k)15.8 m

Interest Paid

688 k647 k553 k
Y, 2016

Financial Leverage

1.7 x

Roka Bioscience Market Value History

Roka Bioscience Online and Social Media Presence

Roka Bioscience Company Life and Culture

You may also be interested in